EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?

Tamiko R Katsumoto iD, Kalin L Wilson, Vinay K Giri, Han Zhu, Shuchi Anand, Kavitha J Ramchandran, Beth A Martin, Muharrem Yunce iD, Srikanth Muppidi

Immunotherapy Advances · 01.01.2022 · 2 (1)

DOI: 10.1093/immadv/ltac012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 27.05.2022. Verfasst von Tamiko R Katsumoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Sanofi and the Koret Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several advanced malignancies leading to durable remission in a subset of patients. Their rapidly expanding use has led to an increased frequency of immune-related adverse events (irAEs). The pathogenesis of irAEs is poorly understood but may involve aberrant activation of T cells leading to inflammatory cytokine release or production of pathogenic antibodies leading to organ damage. Severe irAEs can be extremely debilitating and, in some cases, life threatening. IrAEs may not always be corticosteroid responsive or may require excessively high, often toxic, corticosteroid doses. Therapeutic plasma exchange (PLEX) is a treatment modality that has shown promising results for the management of certain severe irAEs, including irAEs that are not mentioned in current treatment guidelines. PLEX may attenuate ongoing irAEs and prevent delayed irAEs by accelerating clearance of the ICI, or by acutely removing pathogenic antibodies, cytokines, and chemokines. Here, we summarize examples from the literature in which PLEX was successfully used for the treatment of irAEs. We posit that timing may be a critical factor and that earlier utilization of PLEX for life-threatening irAEs may result in more favorable outcomes. In individuals at high risk for irAEs, the availability of PLEX as a potential therapeutic mitigation strategy may encourage life-saving ICI use or rechallenge. Future research will be critical to better define which indications are most amenable to PLEX, particularly to establish the optimal place in the sequence of irAE therapies and to assess the ramifications of ICI removal on cancer outcomes.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmune-related adverse eventimmunotherapyplasmapheresistherapeutic plasma exchange

Autor:innen und Institutionen

  • Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA.

ORCID-Profile: Tamiko R Katsumoto, Muharrem Yunce

Förderung

  • NHLBI NIH HHS
  • Sanofi and the Koret Foundation
  • National Institutes of Health

Zitieren

APA

Katsumoto, T. R., Wilson, K. L., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., Martin, B. A., Yunce, M., & Muppidi, S. (2022). Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. Immunotherapy Advances, 2(1). https://doi.org/10.1093/immadv/ltac012

Vancouver

Katsumoto TR, Wilson KL, Giri VK, Zhu H, Anand S, Ramchandran KJ, et al. Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. Immunotherapy Advances. 2022;2(1). doi:10.1093/immadv/ltac012

BibTeX
@article{Katsumoto2022,
  author = {Katsumoto, Tamiko R and Wilson, Kalin L and Giri, Vinay K and Zhu, Han and Anand, Shuchi and Ramchandran, Kavitha J and Martin, Beth A and Yunce, Muharrem and Muppidi, Srikanth},
  title = {Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?},
  journal = {Immunotherapy Advances},
  year = {2022},
  volume = {2},
  number = {1},
  doi = {10.1093/immadv/ltac012}
}
Kostenlos starten →